A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer
Condition(s):HER-2 Positive Breast Cancer; Malignant Neoplasm of BreastLast Updated:February 2, 2016Terminated
Hide Studies Not Open or Pending
Condition(s):HER-2 Positive Breast Cancer; Malignant Neoplasm of BreastLast Updated:February 2, 2016Terminated
Condition(s):Ovarian NeoplasmsLast Updated:November 22, 2019Completed
Condition(s):Ovarian Epithelial Cancer RecurrentLast Updated:March 27, 2020Completed
Condition(s):Muscle Invasive Bladder CancerLast Updated:September 26, 2019Unknown status
Condition(s):Breast CancerLast Updated:September 21, 2023Active, not recruiting
Condition(s):Non-small Cell Lung CancerLast Updated:January 18, 2010Unknown status
Condition(s):GlioblastomaLast Updated:July 23, 2009Completed
Condition(s):Resistant Solid MalignanciesLast Updated:May 24, 2013Completed
Condition(s):Progression-free Survival; Overall Survival; ToxicityLast Updated:May 19, 2020Withdrawn
Condition(s):Acute Myelogenous LeukemiaLast Updated:February 24, 2021Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.